- OPHTEC has integrated a laser-marked micro ID matrix code (see picture) into the loop junctions of its premium cataract IOLs, aiding identification during the manufacturing process and making production faster and more secure.
- Re-Vana Therapeutics has appointed Michael Nash as Chief Commercial Officer and David Shima as Vice President of Research and Development. They will help lead the company in the development of new sustained-release therapies for conditions including wet AMD, diabetic retinopathy, and glaucoma.
- Samsara Vision will partner with Medevise Consulting to support the development of the next-generation Tsert SI Implantable Miniature Telescope by Isaac Lipshitz, which received its CE Mark in May 2020. The telescope’s foldable haptics allow it to fit into an injector for delivery through a small incision, simplifying the surgical procedure, reducing risk, and halving surgery time.
- Sight Sciences has received FDA clearance for an expanded indication of the OMNI Surgical System: ab-interno canaloplasty followed by trabeculotomy across the spectrum of primary open-angle glaucoma patients.
- The FDA has accepted Visus Therapeutics’ IND to proceed with clinical development of Brimochol, designed as a once-daily drop to correct loss of vision associated with presbyopia. Visus is now initiating its planned phase II clinical trials in the US.
- LENSAR has released financial results from 2020, which saw the company complete its spinoff from PDL BioPharma, grow its laser system base by 10 percent, and continue developing its FLACS solutions. Following a decline in elective surgical procedures in the first half of last year, procedure activity rebounded in the later months, with numbers surpassing the second half of 2019.
